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Abstract
Leukopenia is a common manifestation of SLE. Addition of immunosuppressive therapy in a SLE 
patient who is already leukopenic is a clinical concern. It could worsen leukopenia, increase the 
risk of infection, or both. The aim of this study was to analyze the immediate effect of 
mycophenolate mofetil on the white blood cell count and the rate of infection in SLE patients. Two 
hundred and forty-four patients within the Hopkins Lupus Cohort who were newly started on 
mycophenolate mofetil were included in the study. The white blood cell count and interval 
infection history on the day mycophenolate mofetil was started were compared with the white 
blood cell count and interval infection history at the next visit. The study was based on 244 
patients who began taking mycophenolate mofetil in the cohort. The study population included 
47 % African Americans, 44 % Caucasians, and 9 % other ethnicities. There was a slight but not 
statistically significant increase in the white blood cell count (6.63 vs. 7.01), after starting 
mycophenolate mofetil. Patients with a baseline white blood cell count <3000/mm3 did have a 
statistically significant increase in the white blood cell count after starting mycophenolate mofetil 
(2.57 vs. 5.13, P = 0.0047). We also found a statistically significant increase in the risk of bacterial 
infection (but not viral infection) after starting mycophenolate mofetil (4 vs. 9 %, P = 0.0036). 
Leukopenia does not worsen with mycophenolate mofetil. However, mycophenolate mofetil 
appears to slightly increase the rate of bacterial (but not viral) infection.
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Introduction
Leukopenia is a common manifestation of SLE, occurring in 18–36 % [1, 2]. Both the total 
white blood cell count and lymphocyte count are lower in SLE than in healthy controls [3]. 
Leukopenia is one of the hematological criteria in the 1982 Revised Criteria for 
Classification of Systemic Lupus Erythematosus [4] and in the 1997 update [5]. It is a 
“stand-alone” criterion in the Systemic Lupus International Collaborating Clinics 
Classification Criteria (SLICC) for systemic lupus erythematosus [6].
The SLE literature suggests a variable frequency of leukopenia with the use of 
mycophenolate mofetil. Dooley et al. [7] in the phase 3 trial of mycophenolate mofetil 
versus azathioprine for the maintenance therapy of lupus nephritis found no leukopenia with 
mycophenolate mofetil (0 with mycophenolate mofetil vs. 3.6 % with azathioprine, P = 
0.06). Other studies, many of which were limited by small numbers of patients, reported a 
variable frequency of leukopenia due to mycophenolate mofetil, ranging from 3 to 37 % [8, 
9].
Clinical trials and observational studies have demonstrated a higher frequency of infection in 
SLE patients on mycophenolate mofetil. Appel et al. [10] in an induction study of 
mycophenolate mofetil for lupus nephritis found infection as the most common adverse 
event in both study groups (68.5 % with mycophenolate mofetil; 61.7 % with intravenous 
cyclophosphamide; treatment difference 6.81%; 95 % CI −2.96 to 16.58 %; P = 0.17). 
Dooley et al. [7] also reported infection as the most common adverse event in the 
maintenance study of mycophenolate mofetil for lupus nephritis, with a rate of 79.1 % in the 
mycophenolate mofetil group and 78.4 % in the azathioprine group. In other smaller studies 
of mycophenolate mofetil for lupus nephritis, the reported frequency of infection varied 
from 11 to 50 % [11, 12].
Prospective data from the Hopkins Lupus Cohort provide an opportunity to assess the impact 
of starting mycophenolate mofetil on white blood cell counts and infection. This paper 
presents the results of an analysis comparing results from cohort visits before and after 
starting mycophenolate.
Methodology
Patients and methods
Since 1987, patients with SLE under the care of one rheumatologist at Johns Hopkins 
University School of Medicine were invited to participate in the Hopkins Lupus Cohort. 
Inclusion in the cohort was based on the clinical diagnosis of SLE by the principal 
investigator (MP). The Johns Hopkins University School of Medicine Institutional Review 
Board approved the study yearly. All participants gave written informed consent.
Since initiation of the cohort study in 1987, clinical and laboratory data were prospectively 
collected at each clinic visit in a systematic fashion, according to the Hopkins Lupus Cohort 
protocol. At cohort entry, basic demographic characteristics (date of birth, age at SLE onset, 
ethnicity, sex, years of education, combined annual household income) and presenting 
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clinical manifestations were recorded. Clinical manifestations were assessed through record 
review and patient interview and updated at each subsequent visit. Patients were seen at 
regular intervals of 3 months, or more frequently if medically indicated. At each patient 
visit, vital signs, a complete history, physical examination, and routine laboratory testing 
were performed. The complete white blood count was recorded at every visit, but not 
lymphocyte or neutrophil count. Mycophenolate mofetil doses ranged from 1000 to 3000 mg 
daily.
Definitions of infection—A detailed history of any infections since the last visit, 
including duration of symptoms and use of any antibiotic, was obtained. The start date of 
each infection was recorded. Medical records were reviewed to ascertain the type of interval 
infection. If the patient was symptomatic at a visit, a urine culture was ordered and a urinary 
tract infection was recorded only if positive. A chest X-ray was ordered, and only if 
abnormal was pneumonia diagnosed.
Statistical analysis
We compared the white blood cell count on the day of the visit when mycophenolate mofetil 
was started with the white blood cell count at the next visit, while the patient was continuing 
on mycophenolate mofetil. We also compared the frequency of interval and current infection 
at the visit before and after the start of use of mycophenolate mofetil. To assess the statistical 
significance of observed differences, adjusting for corticosteroid use (which is known to 
affect white blood cell count), we calculated P values based on generalized estimating 
equations.
All statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC, USA).
Results
There were 244 patients who began taking mycophenolate mofetil while in the Hopkins 
Lupus Cohort. This included 114 (47 %) African American, 107 (44 %) Caucasian, and 23 
(9 %) other ethnicities. Of these, 213 (87 %) were female and 31 (13 %) male (Table 1). The 
time between the two study visits ranged from 7 to 120 days, with a median of 47 days.
Table 2 shows the mean white blood cell count at the visit when mycophenolate mofetil was 
started and at the next visit. There was a slight increase in the white blood cell count on 
mycophenolate mofetil, which was not statistically significant. This was true in both 
Caucasians and African Americans. However, in those patients who started with a white 
blood cell count <3000/mm3 before the start of mycophenolate mofetil, there was a 
statistically significant increase in the white blood cell count after starting mycophenolate 
mofetil. This significant association was seen in both Caucasians and African Americans 
when these groups were analyzed separately.
Table 3 demonstrates the change in the white blood cell count after adjustment for ethnicity 
and prednisone. African Americans were found to have a lower white blood cell count 
compared to Caucasians. Prednisone use was associated with a small but significant increase 
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in the white blood cell count. The effect of ethnicity was virtually eliminated in the analysis 
on mycophenolate mofetil.
Of the 19 patients who had a low white blood cell count (<3000/mm3) prior to starting 
mycophenolate mofetil, 16 (84 %) had levels above 3000/mm3 at the follow-up visit. Among 
the 225 who did not have low levels before starting mycophenolate mofetil, 11 (5 %) 
developed low white blood cell counts. Thus, there were fewer patients with low white cell 
counts at the follow-up visit [14] than before starting mycophenolate mofetil [19].
Table 4 shows the changes in white blood cell count by dose of mycophenolate mofetil. At 
every dose, there was a small, non-significant increase in the white blood cell counts.
We compared the visits before and after the start of mycophenolate mofetil with respect to 
the risk of interval and current infection (Table 5). There was a small, statistically significant 
risk of bacterial infection, but no increased risk of viral infection. The mean SLEDAI was 
lower at follow-up (mean = 4.7) than prior to starting MMF (5.9).
Discussion
We found, in SLE patients with baseline leukopenia (white blood cell count <3000/mm3), 
there was a statistically significant increase in the white blood cell count. It is very unlikely 
that this improvement is due to regression to the mean. It is reassuring that on average, white 
blood cell counts increased after starting mycophenolate mofetil in this vulnerable set of 
patients. In previous studies, in SLE patients treated with mycophenolate mofetil, leukopenia 
was reported as a known side effect with variable frequency. Houssiau et al. [13] in the 
MAINTAIN Nephritis study, reported leukopenia in 4 % of the patients (n = 53) on 
mycophenolate mofetil. In another smaller study (n = 26) by Ong et al. [9], leukopenia was 
found in 37 % of the SLE patients on mycophenolate mofetil. The meta-analysis by Feng et 
al. [14] comparing mycophenolate mofetil with azathioprine for maintenance therapy of 
lupus nephritis showed less leukopenia with mycophenolate mofetil than azathioprine (RR 
0.12; 95 % CI 0.04–0.39, P = 0.0004). Touma et al. [15] in their meta-analysis of patients 
with lupus nephritis found no statistical difference in the risk of leukopenia with 
mycophenolate mofetil compared to cyclophosphamide [RR 1.29 (0.35, 4.70)].
Our study was unique in that we compared the white blood cell count before and after the 
start of mycophenolate mofetil therapy. Our study design allowed the patients to be their 
own control. A limitation of our study was that we were not able to compare the effect of 
mycophenolate mofetil on the lymphocyte or neutrophil count, as differential counts were 
not part of the cohort protocol.
The major concern in SLE with mycophenolate mofetil, regardless of leukopenia or 
lymphopenia, is the impact of mycophenolate mofetil on infection risk. In our study, we 
found a statistically significant increase only in the frequency of bacterial infection in SLE 
patients on mycophenolate mofetil. Merrill et al. [16] in the phase III belimumab trial 
demonstrated that the rate of overall infection, including severe and serious infections, was 
higher in SLE patients on mycophenolate than on other immunosuppressives. The effect 
continued during the follow-up period of 4 years. The recent BELONG study, which 
Subedi et al. Page 4
Rheumatol Int. Author manuscript; available in PMC 2017 July 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
evaluated ocrelizumab in SLE patients with lupus nephritis, provided further insight into the 
infection risk of mycophenolate mofetil. Overall, the proportion of patients with infections 
was higher in those receiving background mycophenolate mofetil than in those receiving the 
background Euro-Lupus regimen (consisting of cyclophosphamide followed by 
azathioprine) [17]. Feng et al. [14] in their meta-analysis comparing mycophenolate mofetil 
with azathioprine for the maintenance therapy of lupus nephritis showed no significant 
difference in the risk of infection (RR 0.61, 95 % CI 0.14–2.68). Henderson et al. [18] found 
fewer major infection episodes among lupus nephritis patients on mycophenolate mofetil 
compared with oral cyclophosphamide (1 study, 62 patients; RR 0.21, 95 % CI 0.05–0.89), 
but not intravenous cyclophosphamide (6 studies, 683 patients; RR 1.11, 95 % CI 0.74–
1.68). There was no difference in the risk of herpes zoster infection between the 
mycophenolate mofetil and the intravenous cyclophosphamide group (4 studies, 613 
patients; RR 1.35, 95 % CI 0.71–2.58).
A limitation of our study is that the Hopkins Lupus Cohort visits were outpatient visits, but 
ascertainment of interval infection included any that occurred during an interval 
hospitalization, as well. We acknowledge the limitation that we do not have a ranking of the 
severity of infections reordered in the database. However, the bacterial infections were 
primarily urinary tract infection, bronchitis, sinusitis, and cellulitis. None of these infections 
required hospitalization or intravenous antibiotics. There was one case of progressive 
multifocal leukoencephalopathy (PML) in a patient taking mycophenolate mofetil, but after 
long use (not at first visit after starting), so it was not included in our analysis.
Based on the mechanism of action, mycophenolate mofetil preferentially inhibits the type II 
isoform of inosine-5′-monophosphate (IMPDH), which is expressed exclusively in activated 
T and B lymphocytes. We did not find any statistically significant difference in the 
frequency of viral infection. Our study demonstrates the increased risk of bacterial infection 
in SLE patients taking mycophenolate mofetil and emphasizes the importance of regular 
vaccination against the common infections including influenza and pneumococcus as 
recommended by the European League Against Rheumatism (EULAR) [19]. A careful 
screening for bacterial infections in febrile or symptomatic SLE patients at each visit on 
mycophenolate is warranted. In renal transplant patients on mycophenolate mofetil, viral 
infection is reported as more common, among which cytomegalovirus is a concern. The 
clinical trials of mycophenolate mofetil in SLE patients have not reported cytomegalovirus 
as a common infection nor did we have a single cytomegalovirus infection in our study. We 
cannot explain why we see more of a bacterial infection risk in our SLE population.
Conclusion
In conclusion, in a study design in which SLE patients served as their own control (before 
and during taking mycophenolate mofetil), mycophenolate mofetil did not result in a 
decrease in the white blood cell count. However, bacterial (but not viral) infections were 
significantly increased. The risk of infection from mycophenolate mofetil in SLE cannot be 
assessed by the white blood cell count alone and requires ongoing vigilance on the part of 
both the patient and clinician to ensure early detection and treatment of infection. However, 
our results suggest that mycophenolate mofetil can be started in SLE patients with baseline 
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leukopenia, with the expectation that the white blood cell count is likely to improve, not 
worsen.
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Table 1
Characteristics of the study sample
Variable Number (%)
Sex
Female 213 (87)
Male 31 (13)
Race
African American 114 (47)
Caucasian 107 (44)
Other 23 (9)
Age
<30 74 (30)
30–44 107 (44)
45–59 52 (21)
60+ 11 (5)
Days between visits
<30 51 (21)
30–59 92 (38)
60–89 36 (15)
90–120 65 (27)
Prednisone dose at the time of the first visit
0 53 (22)
1–9 53 (22)
10–19 59 (24)
20+ 77 (32)
Using Prednisone at the time of the second visit
0 32 (13)
1–9 48 (20)
10–19 65 (27)
20+ 99 (41)
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Table 2
Mean ± SD white blood cell count before and after start of mycophenolate mofetil
Patient group Before mycophenolate 
mofetil (×1000 cells/mm3)
After start of mycophenolate 
mofetil (×1000 cells/mm3) P value
a
All patients (n = 244) 6.64 (3.45) 7.01 (3.40) 0.28
African American (n = 114) 6.22 (3.10) 6.57 (3.36) 0.67
Caucasian (n = 107) 7.25 (3.93) 7.35 (3.19) 0.77
Patients with white blood cell <3000/mm3 at baseline (n = 
19)
2.55 (0.37) 4.38 (1.42) <0.0001
a
Based on a model, which adjusted for corticosteroid use
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Table 3
Mean WBC by prednisone dose and race, before and after starting of mycophenolate mofetil
Subgroup Before starting MMF After starting MMF
Mean (SD) WBC P value Mean (SD) WBC P value
Prednisone dose
None 5.02 (3.26) <0.0001a 5.27 (2.21) <0.0001a
1–9 5.97 (2.21) 5.46 (2.20)
10–19 6.40 (3.29) 7.14 (3.80)
20+ 8.40 (3.72) 8.25 (3.41)
Race/ethnicity
Caucasian 7.25 (3.93) 0.0099b 7.35 (3.19) 0.049b
African American 6.22 (3.10) 6.57 (3.36)
Other 5.92 (2.13) 7.64 (4.31)
a
Based on a model that assumes a linear relationship between prednisone dose and mean WBC adjusting for race/ethnicity
b
Based on a model adjusting for prednisone dose
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Table 4
Mean ± SD white blood cell count before and after start of mycophenolate mofetil, by dose
Dosea Before mycophenolate mofetil (×1000 
cells/mm3)
After start of mycophenolate mofetil (×1000 
cells/mm3) P value
b
<1000 (n = 11) 5.68 (2.18) 6.64 (2.36) 0.14
1000–1500 (n = 69) 6.52 (3.65) 6.63 (3.14) 0.81
2000–2500 (n = 132) 6.85 (3.55) 7.24 (3.65) 0.30
3000 (n = 21) 6.97 (3.35) 7.32 (3.28) 0.76
a
Dose information missing for 11 patients
b
Based on a model, which adjusted for corticosteroid use
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Table 5
Number (%) with infectiona at the clinic visits immediately before and after start of mycophenolate mofetil
Variable Before mycophenolate mofetil n (%) After mycophenolate mofetil n (%) Adjusted P valueb
Infection (viral or bacterial) 33 (14 %) 46 (19 %) 0.0019
Viral infection 27 (11 %) 27 (11 %) 0.51
Bacterial infection 9 (4 %) 23 (9 %) 0.0036
a
Most common infections: urinary tract infection, bronchitis, sinusitis, and cellulitis
bP value adjusted for prednisone dose
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